Inactive Instrument

Analyst Reco. ProNAi Therapeutics Inc Nasdaq

Equities

Oppenheimer Downgrades Sierra Oncology to Perform From Outperform, Adjusts Price Target to $55 From $45	22-04-14	MT
Jefferies Downgrades Sierra Oncology to Hold From Buy, Adjusts Price Target to $55 From $39	22-04-14	MT
HC Wainwright Downgrades Sierra Oncology to Neutral from Buy, Adjusts Price target to $55 from $51	22-04-13	MT
FTSE Edges Lower, March Inflation Data Seen Securing Another BoE Rate Rise in May	22-04-13	DJ
Oppenheimer Adjusts Sierra Oncology Price Target to $45 From $38, Maintains Outperform Rating	22-03-14	MT
HC Wainwright Adjusts Sierra Oncology's Price Target to $51 From $35, Reiterates Buy Rating	22-01-31	MT
Oppenheimer Adjusts Sierra Oncology's Price Target to $38 From $32, Maintains Outperform Rating	22-01-27	MT
Oppenheimer Adjusts Sierra Oncology's Price Target to $32 From $29, Maintains Outperform Rating	22-01-19	MT
Cantor Fitzgerald Adjusts Sierra Oncology's Price Target to $39 From $33, Maintains Overweight Rating	21-11-30	MT
HC Wainwright Adjusts Sierra Oncology PT to $35 From $29, Maintains Buy Rating	21-11-05	MT
SIERRA ONCOLOGY : Cantor Fitzgerald Starts Sierra Oncology at Overweight with $33 Price Target	21-09-27	MT
SIERRA ONCOLOGY : Oppenheimer Adjusts Sierra Oncology PT to $29 From $27, Maintains Outperform Rating	20-12-17	MT
SIERRA ONCOLOGY : HC Wainwright Starts Sierra Oncology at Buy With $29 Price Target	20-12-11	MT
Sierra Oncology, Inc. Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib	18-12-03	CI

No results for this search